University Medical Center Nijmegen

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, University Medical Center Nijmegen sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting upper half by trial count

University Medical Center Nijmegen: 1 sponsored US clinical trial, 1 recruiting.

University Medical Center Nijmegen sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. The most-studied condition in this pipeline is BRIP1 Gene Mutation, with 1 trials.

Mid-pack sponsor footprint

University Medical Center Nijmegen is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

What is open in the University Medical Center Nijmegen pipeline

1 recruiting of 1 indexed (100% open).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: BRIP1 Gene Mutation (1 trial), 5 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University Medical Center Nijmegen: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

University Medical Center Nijmegen sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share University Medical Center Nijmegen1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
University Medical Center Nijmegen sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University Medical Center Nijmegen sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

What to do with this University Medical Center Nijmegen page

1 registered trials is a research-attention snapshot, not an endorsement of University Medical Center Nijmegen or any single study.

  • 1 of University Medical Center Nijmegen's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • BRIP1 Gene Mutation is the condition University Medical Center Nijmegen studies most, compare against other sponsors active in the same condition before evaluating a specific study. See BRIP1 Gene Mutation trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

University Medical Center Nijmegen pipeline card: 1 registered trials from official public datasets.Report a data error.